Where does 10x Genomics, Inc.'s cash flow data come from?

Every line is extracted from 10x Genomics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

10x Genomics, Inc. TXG Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	-$43.54M+76.2%	-$182.63M+28.4%	-$255.1M-53.7%	-$166M-185%
Depreciation and amortization	$36.2M+0.9%	$35.88M+1.0%	$35.51M+40.0%	$25.37M+20.1%
Stock-based compensation	$109.12M-22.5%	$140.75M-15.7%	$166.95M+22.0%	$136.85M+42.6%
Impairment charges	$1.25M—	$0—	$0—	$0—
Change in accounts receivable	-$44.55M—	——	——	$18.95M-44.3%
Change in inventories	-$27.95M—	——	-$7.87M-137%	$21.19M-29.7%
Change in accounts payable	-$2.13M+36.6%	-$3.35M+44.3%	-$6.02M—	——
Change in accrued liabilities	$7.65M+109%	$3.65M—	——	——
Change in other assets	——	——	——	——
Change in other liabilities	$1.4M+79.9%	$776K-40.2%	$1.3M+143%	-$3M+39.1%
Other working capital changes	-$1.75M-407%	$571K—	——	$1.96M+2,377%
Change in deferred revenue	$746K-93.3%	$11.21M+2.5%	$10.93M+226%	$3.35M+118%
Non-cash operating lease expense	——	——	——	——
Change in operating lease liabilities	-$10.31M+17.4%	-$12.48M-44.0%	-$8.67M-35.0%	-$6.42M—
Change in receivables	——	——	$0—	——
Net cash from operating activities	$136.05M—	——	——	——
Capital expenditures	$5.94M-52.1%	$12.39M-74.5%	$48.6M-63.1%	$131.66M+30.0%
Purchases of investments	$123.44M—	——	$0-100%	$282.87M—
Proceeds from maturities/sales of investments	$125.2M—	——	$82.83M+347%	$18.53M—
Net cash from investing activities	-$13.44M+58.8%	-$32.63M-124%	$137.95M+139%	-$350.89M-229%
Proceeds from issuance of common stock	$6.8M-37.7%	$10.91M-44.0%	$19.48M—	$0—
Other financing activities	——	——	——	——
Net cash from financing activities	$6.8M-37.7%	$10.91M-20.2%	$13.67M-13.6%	$15.82M-55.2%
Effect of exchange rate changes on cash	$517K+415%	-$164K—	——	——
Net increase (decrease) in cash	$129.9M+954%	-$15.22M—	——	-$368.72M-279%
Income taxes paid	$2.39M-57.6%	$5.64M+14.5%	$4.93M+25.5%	$3.93M-54.7%
Asset Acquisition, Gain (Loss) Contingent Consideration, Change In Fair Value Disclosure	——	——	$0—	——
Accrued expenses and other current liabilities	——	——	$28.3M+748%	$3.34M—
Deferred revenue	$746K-93.3%	$11.21M+2.5%	$10.93M+226%	$3.35M+118%
Accrued compensation and employee benefits	$7.65M+109%	$3.65M—	——	——
Operating lease liabilities	-$10.31M+17.4%	-$12.48M-44.0%	-$8.67M-35.0%	-$6.42M—
Other long-term liabilities	$1.4M+79.9%	$776K-40.2%	$1.3M+143%	-$3M+39.1%
Increase (Decrease) in Other Operating Assets	——	——	——	-$967K+7.5%
Increase (Decrease) in Other Receivables	——	——	$0—	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——
Lease impairment charges	——	——	$9.86M—	——
Operating lease right-of-use asset amortization	——	——	——	——
Restructuring charges, net of cash paid (Note 15)	$1.25M—	$0—	$0—	——
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$125.2M—	——	$82.83M+347%	$18.53M—
Proceeds from exercises of stock options and other stock issuances	$6.8M-37.7%	$10.91M-44.0%	$19.48M-8.2%	$21.23M-47.4%
Accrued payables for capital expenditures	——	——	——	$29.29M+72.6%
Increase Decrease In Operating Lease Liability	-$10.31M+17.4%	-$12.48M-44.0%	-$8.67M-35.0%	-$6.42M—
Issuance of common stock for the acquisition of Ansys	——	——	——	——
Income Taxes Paid, Net	$2.39M-57.6%	$5.64M+14.5%	$4.93M+25.5%	$3.93M-54.7%
Free cash flow	$130.12M—	——	——	-$165.27M-34.7%
Free cash flow	$130.12M—	——	——	-$165.27M-34.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does 10x Genomics, Inc.'s cash flow data come from?: Every line is extracted from 10x Genomics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.